title: Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
authors: philippe.moreau@chu-nantes.fr.
authors: Anne
authors: A
authors: Lok
authors: Julie
authors: J
authors: Mocquard
authors: Jessie
authors: J
authors: Bourcier
authors: Laurence
authors: L
authors: Redelsperger
authors: Antoine
authors: A
authors: Bonnet
authors: Cecile
authors: C
authors: Chauvin
authors: Patrick
authors: P
authors: Thomaré
authors: Beatrice
authors: B
authors: Mahé
authors: Cyrille
authors: C
authors: Touzeau
authors: Philippe
authors: P
authors: Moreau
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D010523:Peripheral Nervous System Diseases / Q000209:etiology; D011446:Prospective Studies; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone
keywords: ASCT; VTD; multiple myeloma; subcutaneous bortezomib